Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Protocols for Developing Novel Chikungunya Virus DNA Vaccines.

Chung C, Ugen KE, Sardesai NY, Weiner DB, Muthumani K.

Methods Mol Biol. 2016;1426:311-32. doi: 10.1007/978-1-4939-3618-2_28.

PMID:
27233283
2.

Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy.

Flingai S, Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE, Sardesai NY, Muthumani K, Weiner DB.

Sci Rep. 2015 Jul 29;5:12616. doi: 10.1038/srep12616.

3.

HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.

Muthumani K, Wise MC, Broderick KE, Hutnick N, Goodman J, Flingai S, Yan J, Bian CB, Mendoza J, Tingey C, Wilson C, Wojtak K, Sardesai NY, Weiner DB.

PLoS One. 2013 Dec 31;8(12):e84234. doi: 10.1371/journal.pone.0084234. eCollection 2013.

4.

Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity.

Shedlock DJ, Tingey C, Mahadevan L, Hutnick N, Reuschel EL, Kudchodkar S, Flingai S, Yan J, Kim JJ, Ugen KE, Weiner DB, Muthumani K.

Vaccines (Basel). 2014 Mar 25;2(2):196-215. doi: 10.3390/vaccines2020196.

5.

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.

Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB.

Front Immunol. 2013 Nov 4;4:354. doi: 10.3389/fimmu.2013.00354. Review.

6.

Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.

Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB.

Hum Vaccin Immunother. 2013 Oct;9(10):2253-62. doi: 10.4161/hv.26498. Epub 2013 Sep 17.

Supplemental Content

Loading ...
Support Center